Monotherapy for treating type 2 diabetes (NICE TA390)
Canagliflozin, dapagliflozin and empagliflozin as monotherapies are recommended as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if:
- a dipeptidyl peptidase‑4 (DPP‑4) inhibitor would otherwise be prescribed and
- a sulfonylurea or pioglitazone is not appropriate.
The LSCMMG recommends canagliflozin as the 2nd line ““gliflozin”” (1st line dapagliflozin or empagliflozin).
Reason for decision:
Suitable for initiation in primary care